Stock GTHX G1 THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
4.49 USD +1.13% Intraday chart for G1 Therapeutics, Inc. +12.53% +47.21%
05-01 Transcript : G1 Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024
05-01 Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
GL
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
GL
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
AQ
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
AQ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
GL
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
AQ
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
AQ
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
GL
Life Sciences Ontario Announces Recipients of 2024 LSO Awards
AQ
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
GL
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
AQ
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
GL
Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 | Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.
AQ
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GTHX Stock
  4. News G1 Therapeutics, Inc.
  5. Press Releases